SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

SRX Global Updates Engineered T-Cell Strategy After Pfizer-Starna Licensing Agreement

SRX Global provided an update on its engineered T-cell strategy following a Pfizer-Starna licensing agreement. The available body text is truncated.

CEROSRXH

Related stories